Loading...
•
Mar 31, 2024
Ultragenyx Q1 2024 Earnings Report
Ultragenyx reported Q1 2024 financial results with total revenue of $109 million and reaffirmed its 2024 financial guidance.
Key Takeaways
Ultragenyx reported $109 million in total revenue for the first quarter of 2024, representing 8% growth compared to the same period in 2023. Crysvita revenue was $83 million, a 9% increase year-over-year, while Dojolvi revenue was $16 million, a 14% increase year-over-year. The company reaffirmed its full-year 2024 revenue guidance.
Total revenue for Q1 2024 was $109 million, an 8% increase compared to Q1 2023.
Crysvita revenue for Q1 2024 was $83 million, a 9% increase compared to Q1 2023.
Dojolvi revenue for Q1 2024 was $16 million, a 14% increase compared to Q1 2023.
The company reaffirms 2024 total revenue guidance between $500 million to $530 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Ultragenyx reaffirms its full-year 2024 financial guidance, with total revenue expected to be in the range of $500 million to $530 million, Crysvita revenue in the range of $375 million to $400 million, and Dojolvi revenue in the range of $75 million to $80 million. Net Cash Used in Operations to be less than $400 million
Positive Outlook
- Total revenue in the range of $500 million to $530 million
- Crysvita revenue in the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
- Dojolvi revenue in the range of $75 million to $80 million
- Net Cash Used in Operations to be less than $400 million
- Expect additional Phase 2 data update in second half of 2024
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...